pmid
stringlengths 8
12
| sentence
stringlengths 59
1.08k
| cancer_type
stringclasses 3
values | gene
dict | cancer
dict | CGE
stringclasses 2
values | CCS
stringclasses 3
values | PT
stringclasses 3
values | IGE
stringclasses 4
values | expression_change_keyword_1
dict | expression_change_keyword_2
dict |
|---|---|---|---|---|---|---|---|---|---|---|
18497984.s5 | In 2 cell lines with weak expression of TUBB3 protein (OVCAR-3 and JHOC-8), TUBB3 induction was independently induced by treatment with 5-Aza-CdR (JHOC-8) or PBA (OVCAR-3), while neither agent markedly altered TUBB3 mRNA/protein expression in a strongly TUBB3-expressing cell line (JHOC-5). | ovarian | {
"name": "TUBB3",
"pos": [
76,
80
]
} | {
"name": "OVCAR-3",
"pos": [
55,
61
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induction",
"pos": [
82,
90
],
"type": "Positive_regulation"
} |
||
18497984.s7 | A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3. | ovarian | {
"name": "TUBB3",
"pos": [
118,
122
]
} | {
"name": "OVCAR-3",
"pos": [
77,
83
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
124,
133
],
"type": "Gene_expression"
} | {
"name": "induced",
"pos": [
139,
145
],
"type": "Positive_regulation"
} |
||
8244317.s0 | p53 accumulation in ovarian carcinomas and its prognostic implications. | ovarian | {
"name": "p53",
"pos": [
0,
2
]
} | {
"name": "ovarian carcinomas",
"pos": [
20,
37
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "accumulation",
"pos": [
4,
15
],
"type": "Positive_regulation"
} |
8244317.s11 | These results suggest that p53 accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with ovarian carcinoma. | ovarian | {
"name": "p53",
"pos": [
27,
29
]
} | {
"name": "ovarian carcinoma",
"pos": [
195,
211
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "accumulation",
"pos": [
31,
42
],
"type": "Positive_regulation"
} |
12174904.s0 | Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. | ovarian | {
"name": "MDR1-gene",
"pos": [
13,
21
]
} | {
"name": "ovarian cancer",
"pos": [
62,
75
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
23,
32
],
"type": "Gene_expression"
} | {
"name": "Induction",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
||
9114434.s0 | Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. | ovarian | {
"name": "gamma-glutamyl transpeptidase mRNA",
"pos": [
13,
46
]
} | {
"name": "ovarian carcinoma",
"pos": [
81,
97
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Induction",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
||
9114434.s2 | Our previous studies have shown that sublines of human ovarian carcinoma cell line A2780, which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of gamma-glutamyl transpeptidase (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2) [El-akawi et al., Cancer Lett. 105:5-14; 1966]. | ovarian | {
"name": "gamma-glutamyl transpeptidase",
"pos": [
207,
235
]
} | {
"name": "ovarian carcinoma",
"pos": [
55,
71
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
154,
161
],
"type": "Positive_regulation"
} |
10498868.s6 | Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer. | ovarian | {
"name": "ING1",
"pos": [
86,
89
]
} | {
"name": "ovarian cancers",
"pos": [
46,
60
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
91,
100
],
"type": "Gene_expression"
} | {
"name": "repression",
"pos": [
72,
81
],
"type": "Negative_regulation"
} |
||
3465487.s0 | Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation. | ovarian | {
"name": "CA-125",
"pos": [
70,
75
]
} | {
"name": "ovarian tumor",
"pos": [
48,
60
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increases",
"pos": [
11,
19
],
"type": "Positive_regulation"
} |
16552954.s0 | [Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice]. | ovarian | {
"name": "TRAIL gene",
"pos": [
55,
64
]
} | {
"name": "ovarian carcinoma",
"pos": [
82,
98
]
} | increased | cancerTOnormal | observation | unidentifiable | {
"name": "transfection",
"pos": [
66,
77
],
"type": "Gene_expression"
} | {
"name": "transfection",
"pos": [
66,
77
],
"type": "Positive_regulation"
} |
22312289.s3 | Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level. | ovarian | {
"name": "cyclin A",
"pos": [
88,
95
]
} | {
"name": "ovarian cancer",
"pos": [
124,
137
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
33,
40
],
"type": "Positive_regulation"
} |
||
22312289.s3 | Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in ovarian cancer cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of p27 at only the protein expression level without change in its mRNA level. | ovarian | {
"name": "p27",
"pos": [
230,
232
]
} | {
"name": "ovarian cancer",
"pos": [
124,
137
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decrease",
"pos": [
218,
225
],
"type": "Negative_regulation"
} |
||
12066248.s0 | Abdominopelvic tuberculosis simulating disseminated ovarian carcinoma with elevated CA-125 level: report of two cases. | ovarian | {
"name": "CA-125",
"pos": [
84,
89
]
} | {
"name": "ovarian carcinoma",
"pos": [
52,
68
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
75,
82
],
"type": "Positive_regulation"
} |
11104617.s10 | Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis. | ovarian | {
"name": "CA 125",
"pos": [
38,
43
]
} | {
"name": "Ovarian cancer",
"pos": [
0,
13
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
29,
36
],
"type": "Positive_regulation"
} |
21740819.s7 | The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells. | ovarian | {
"name": "VEGF-A protein and mRNA",
"pos": [
72,
94
]
} | {
"name": "ovarian cancer",
"pos": [
145,
158
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
96,
105
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
62,
70
],
"type": "Negative_regulation"
} |
21740819.s8 | This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. | ovarian | {
"name": "VEGF-A",
"pos": [
75,
80
]
} | {
"name": "ovarian cancer",
"pos": [
129,
142
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
82,
91
],
"type": "Gene_expression"
} | {
"name": "decrease",
"pos": [
66,
73
],
"type": "Negative_regulation"
} |
10397458.s4 | Patients with invasive ovarian cancer were found to have significantly higher median c-erbB-2 oncoprotein expression than patients with either benign ovarian cyst (P = 0.002) or control groups (P = 0.001). | ovarian | {
"name": "c-erbB-2 oncoprotein",
"pos": [
85,
104
]
} | {
"name": "ovarian cancer",
"pos": [
23,
36
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
106,
115
],
"type": "Gene_expression"
} | {
"name": "higher",
"pos": [
71,
76
],
"type": "Positive_regulation"
} |
10397458.s5 | Overexpression of c-erbB-2 oncoprotein was found in seven (21.9%) of 32 epithelial ovarian cancers. | ovarian | {
"name": "c-erbB-2 oncoprotein",
"pos": [
18,
37
]
} | {
"name": "epithelial ovarian cancers",
"pos": [
72,
97
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "Overexpression",
"pos": [
0,
13
],
"type": "Gene_expression"
} | {
"name": "Overexpression",
"pos": [
0,
13
],
"type": "Positive_regulation"
} |
14516936.s3 | BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types. | ovarian | {
"name": "BRCA1",
"pos": [
0,
4
]
} | {
"name": "ovarian cancers",
"pos": [
91,
105
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
6,
15
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
20,
28
],
"type": "Negative_regulation"
} |
19935792.s5 | CCBE1 is expressed in normal ovary, but is reduced in ovarian cancer cell lines and primary carcinomas. | ovarian | {
"name": "CCBE1",
"pos": [
0,
4
]
} | {
"name": "ovarian cancer",
"pos": [
54,
67
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "reduced",
"pos": [
43,
49
],
"type": "Negative_regulation"
} |
19935792.s6 | Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer. | ovarian | {
"name": "CCBE1",
"pos": [
84,
88
]
} | {
"name": "ovarian cancer",
"pos": [
47,
60
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "re-induced",
"pos": [
73,
82
],
"type": "Positive_regulation"
} |